[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Ethics::
peer-review::
Indexing::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Journal DOI

AWT IMAGE

..
Copyright Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 
This Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0
..
:: Volume 24, Issue 1 (3-2022) ::
J Babol Univ Med Sci. 2022; Volume 24 Back to browse issues page
The Effect of Mesalazine on Pain Management in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
M Khosravi , SH Abedi Voluklaei * , H Najafzadeh Varzi , H Gholinia
1.Department of Internal Medicine, School of Medicine, Babol University of Medical Sciences, Babol, I.R Iran. , h.abedi@mubabol.ac.ir
Abstract:   (4964 Views)
Background and Objective: Irritable bowel syndrome is one of the common gastrointestinal complaints that is often resistant to standard treatment. Since mesalazine reduces abdominal pain and diarrhea through its anti-inflammatory effects, this study was conducted to investigate the effect of mesalazine on pain management in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Methods: This case-control study was conducted among 100 patients diagnosed with diarrhea-predominant irritable bowel syndrome referred to Ayatollah Rouhani Hospital in Babol. Patients were randomly divided into two groups of 50, receiving standard treatment (amitriptyline 25 mg) and a group that received mesalazine at a dose of 500 mg for 4 weeks three times a day in addition to standard treatment. Subjects were examined and compared in terms of pain intensity and frequency of discharge and recovery.
Findings: The intensity of pain after treatment in the case group was lower than before treatment (4.66±2.29 vs. 7.80±2.01) (p=0.004). Out of 50 patients, 38 people (76.0%) in the case group and only 20 people (40%) in the control group recovered (p<0.001). In the case group, the number of bowel movements after treatment (2.20±0.92) was significantly less than before (4.92±0.92) (p<0.001). In the control group, the number of bowel movements showed a statistically significant difference before and after treatment (5.22±1.07 vs. 2.50±1.19) (p<0.001).
Conclusion: Based on the results of this study, mesalazine is significantly effective in reducing the intensity of pain caused by irritable bowel syndrome. However, there was no difference in the number of excretions.
Keywords: Mesalazine, Amitriptyline, Irritable Bowel Syndrome, Diarrhea, Abdominal Pain.
Full-Text [PDF 423 kb]   (819 Downloads)    
Type of Study: Case-Control | Subject: Internal (Digestive)
Received: 2021/07/25 | Accepted: 2021/11/10 | Published: 2022/09/18
Send email to the article author



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khosravi M, Abedi Voluklaei S, Najafzadeh Varzi H, Gholinia H. The Effect of Mesalazine on Pain Management in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. J Babol Univ Med Sci 2022; 24 (1) :363-371
URL: http://jbums.org/article-1-10253-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 24, Issue 1 (3-2022) Back to browse issues page
مجله علمی دانشگاه علوم پزشکی بابل Journal of Babol University of Medical Sciences

The Journal of Babol University of Medical Sciences is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Persian site map - English site map - Created in 0.06 seconds with 43 queries by YEKTAWEB 4639